Key result
Metabolically unhealthy overweight/obesity linked to ~160% higher risk of sustained uncontrolled hypertension vs normal weight.
Why the study?
Whether metabolic health and obesity status affect blood pressure control in patients receiving single-pill combination treatment remained unknown.
Do metabolic health and obesity status affect the risk of uncontrolled blood pressure phenotypes in patients receiving single-pill combination antihypertensive treatment?
Cohort (n=685)
Do metabolic health and obesity status affect the risk of uncontrolled blood pressure phenotypes in patients receiving single-pill combination antihypertensive treatment?
Metabolically unhealthy and overweight/obese patients receiving single-pill combination antihypertensive therapy are at significantly higher risk for sustained and morning uncontrolled hypertension, highlighting the need for ambulatory blood pressure monitoring in this population.
May warrant enhanced surveillance in metabolically unhealthy overweight patients on combination therapy; leaves open whether phenotype-specific strategies improve control.
BACKGROUND AND AIMS: Metabolic status and obesity are considered to be related to the risk of hypertension. However, whether metabolic health and obesity status affect blood pressure (BP) control remains unknown. This study aimed to explore the prevalence of BP phenotypes in patients receiving single-pill combination (SPC) treatment and the associations of metabolic health and obesity status with BP phenotypes. METHODS AND RESULTS: Overall, 685 untreated patients completed the 4-week follow-up in this prospective study. Participants were divided into four groups according to their metabolic health and obesity status. The prevalence of white-coat uncontrolled hypertension, controlled hypertension, masked uncontrolled hypertension (MUCH), sustained uncontrolled hypertension (SUCH) and uncontrolled morning hypertension (UMH) was 2.6 %, 23.0 %, 44.3 %, 30.1 % and 51.1 %, respectively. The metabolically unhealthy overweight/obesity (MUO) group had the highest prevalence of SUCH and UMH, and the highest 24-h, daytime, nighttime, and morning systolic and diastolic BP. In the multivariate logistic analysis, compared with the metabolically healthy normal weight (MHNW) phenotype, the MUO phenotype was associated with increased risks of SUCH (odds ratio (OR) = 2.601, 95 % confidence interval (CI): 1.109-6.099) and UMH (OR = 2.689, 95 % CI: 1.504-4.809). The metabolically healthy overweight/obesity (MHO) phenotype had an increased risk of UMH (OR = 2.277, 95 % CI: 1.014-5.111). CONCLUSION: The prevalence of MUCH, SUCH and UMH was high among patients receiving SPC treatment. MHO and MUO individuals are at increased risk for uncontrolled hypertension. Therefore, metabolic health and obesity status should be taken into consideration, and the use of ABPM should be applied to intensify treatment when managing hypertension. REGISTRATION NUMBER: ChiCTR2200059719.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) conducted a cohort in hypertension (n=685). Metabolically unhealthy overweight/obesity (MUO) vs. Metabolically healthy normal weight (MHNW) was evaluated on sustained uncontrolled hypertension (SUCH) (OR 2.601, 95% CI 1.109-6.099). The metabolically unhealthy overweight/obesity phenotype was associated with an increased risk of sustained uncontrolled hypertension compared to normal weight (OR 2.601; 95% CI 1.109-6.099).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: